obtained data from a random sample from a very large health claims database in order to explore and model the associations between the use of GLP-1 agonists (compared to bupropion-naltrexone) and gastrointestinal adverse events (biliary disease, pancreatitis, bowel obstruction, and gastroparesis). This evidence concerns the gene GCG and gastroparesis.